TissGeneSummary for CLDN2 |
Gene summary |
Basic gene information | Gene symbol | CLDN2 |
Gene name | claudin 2 | |
Synonyms | - | |
Cytomap | UCSC genome browser: Xq22.3-q23 | |
Type of gene | protein-coding | |
RefGenes | NM_001171092.1, NM_001171095.1,NM_020384.3, | |
Description | SP82claudin-2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 300520 | |
HGNC : HGNC | ||
Ensembl : ENSG00000165376 | ||
HPRD : 06471 | ||
Vega : OTTHUMG00000022154 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_CLDN2 | |
BioGPS: 9075 | ||
Pathway | NCI Pathway Interaction Database: CLDN2 | |
KEGG: CLDN2 | ||
REACTOME: CLDN2 | ||
Pathway Commons: CLDN2 | ||
Context | iHOP: CLDN2 | |
ligand binding site mutation search in PubMed: CLDN2 | ||
UCL Cancer Institute: CLDN2 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | ColonKidney | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | COADKIRC,KIRP,KICH | |
Reference showing the relevant tissue of CLDN2 | ||
Description by TissGene annotations | Cancer gene Have significant anti-correlated miRNA |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for CLDN2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
KICH | -0.751671388 | 5.746908612 | -6.49858 | 4.33E-14 | 6.72E-13 |
BRCA | -2.067147493 | -0.106222055 | -1.960925439 | 9.26E-19 | 6.03E-18 |
LIHC | 4.672540612 | 6.850338612 | -2.177798 | 1.07E-05 | 4.48E-05 |
THCA | 2.047449697 | -0.141960473 | 2.189410169 | 7.23E-10 | 4.27E-09 |
LUSC | -0.25083382 | 1.869158337 | -2.119992157 | 4.72E-08 | 1.37E-07 |
COAD | 5.056402304 | 0.359413843 | 4.696988462 | 1.52E-08 | 1.29E-07 |
PRAD | -2.879034234 | -0.772716927 | -2.106317308 | 0.00136 | 0.004209613 |
KIRC | 7.84618489 | 6.68729739 | 1.1588875 | 0.00122 | 0.002272668 |
STAD | 5.035722737 | 1.692635237 | 3.3430875 | 4.24E-05 | 0.000376908 |
Top |
TissGene-miRNA for CLDN2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
LUAD | hsa-miR-195-5p | MIMAT0000461 | 0.032 | -0.28 | 60 |
LUAD | hsa-miR-16-5p | MIMAT0000069 | 0.0092 | -0.34 | 60 |
Top |
TissGeneMut for CLDN2 |
TissGeneSNV for CLDN2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.M156I | SKCM | 2 |
p.M52I | SKCM | 2 |
p.G101A | UVM | 1 |
p.G5S | SARC | 1 |
p.C108F | LUSC | 1 |
p.F183Y | COAD | 1 |
p.L27F | THYM | 1 |
p.W138C | UCEC | 1 |
p.C54Y | UCEC | 1 |
p.C54F | SKCM | 1 |
p.L6I | LUAD | 1 |
p.W51C | CESC | 1 |
p.K157Q | BLCA | 1 |
p.S34F | UCEC | 1 |
p.G129S | SKCM | 1 |
p.C95Y | LGG | 1 |
p.C108F | LUAD | 1 |
p.G101A | HNSC | 1 |
p.M83I | LUAD | 1 |
p.T56K | OV | 1 |
p.G37S | LGG | 1 |
p.L18P | HNSC | 1 |
p.E110K | SKCM | 1 |
p.M102I | CESC | 1 |
p.M156I | BLCA | 1 |
p.G37D | ESCA | 1 |
Top |
TissGeneCNV for CLDN2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for CLDN2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for CLDN2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for CLDN2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for CLDN2 |
TissGeneDrug for CLDN2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for CLDN2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0006142 | Malignant neoplasm of breast | 6 | BeFree |
umls:C0021390 | Inflammatory Bowel Diseases | 6 | BeFree,LHGDN |
umls:C0678222 | Breast Carcinoma | 6 | BeFree |
umls:C0001418 | Adenocarcinoma | 4 | BeFree,LHGDN |
umls:C0027627 | Neoplasm Metastasis | 4 | BeFree |
umls:C0494165 | Secondary malignant neoplasm of liver | 4 | BeFree |
umls:C0596263 | Carcinogenesis | 4 | BeFree |
umls:C1527249 | Colorectal Cancer | 4 | BeFree |
umls:C0009319 | Colitis | 3 | BeFree |
umls:C0009402 | Colorectal Carcinoma | 3 | BeFree |
umls:C0007102 | Malignant tumor of colon | 2 | BeFree |
umls:C0009324 | Ulcerative Colitis | 2 | BeFree |
umls:C0699790 | Colon Carcinoma | 2 | BeFree |
umls:C0001430 | Adenoma | 1 | LHGDN |
umls:C0004623 | Bacterial Infections | 1 | BeFree |
umls:C0007095 | Carcinoid Tumor | 1 | BeFree |
umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | BeFree |
umls:C0007137 | Squamous cell carcinoma | 1 | LHGDN |
umls:C0008325 | Cholecystitis | 1 | LHGDN |
umls:C0008350 | Cholelithiasis | 1 | BeFree |
umls:C0009404 | Colorectal Neoplasms | 1 | LHGDN |
umls:C0010346 | Crohn Disease | 1 | BeFree |
umls:C0021400 | Influenza | 1 | BeFree |
umls:C0024623 | Malignant neoplasm of stomach | 1 | BeFree |
umls:C0025568 | Metaplasia | 1 | LHGDN |
umls:C0030305 | Pancreatitis | 1 | BeFree,CTD_human |
umls:C0036117 | Salmonella infections | 1 | BeFree |
umls:C0036220 | Kaposi Sarcoma | 1 | BeFree |
umls:C0149521 | Pancreatitis, Chronic | 1 | BeFree |
umls:C0153676 | Secondary malignant neoplasm of lung | 1 | BeFree |
umls:C0153687 | Secondary malignant neoplasm of skin | 1 | BeFree |
umls:C0178874 | Tumor Progression | 1 | BeFree |
umls:C0206624 | Hepatoblastoma | 1 | BeFree |
umls:C0275524 | Coinfection | 1 | BeFree |
umls:C0278488 | Carcinoma breast stage IV | 1 | BeFree |
umls:C0520459 | Necrotizing Enterocolitis | 1 | BeFree |
umls:C0685938 | Malignant neoplasm of gastrointestinal tract | 1 | BeFree |
umls:C0686619 | Secondary malignant neoplasm of lymph node | 1 | BeFree |
umls:C0856727 | Cholesterol gallstones | 1 | BeFree |
umls:C0947622 | Cholecystolithiasis | 1 | BeFree |
umls:C1458155 | Mammary Neoplasms | 1 | LHGDN |